Bristol Post-Accounting Focus Will Be On R&D Investment, Investor Relations
Executive Summary
Maximizing Bristol-Myers Squibb's R&D return on investment will be one of the biggest challenges facing the company as it comes out of its accounting reforms, CFO Andrew Bonfield said
You may also be interested in...
Bristol Restates, But Reforms Continue; Q3 Charges Show Old Habits Die Hard
Bristol is taking steps to create a more open environment for internal communications as part of ongoing reforms to its financial controls
Bristol Renounces Late-Listed Patents Under FTC Settlement
Bristol-Myers Squibb is surrendering its rights to a 30-month stay of approval in litigation over patents issued after an ANDA is on file at FDA
Bristol Abilify To Launch In Late November; Antipsychotic Approved Nov. 15
Bristol-Myers Squibb/Otsuka's Abilify (aripiprazole) will be launched by the end of November following FDA's Nov. 15 approval of the atypical antipsychotic